Evaluation and medical management of benign prostatic hyperplasia

Mayo Clin Proc. 2005 Oct;80(10):1356-62. doi: 10.4065/80.10.1356.

Abstract

Benign prostatic hyperplasia (BPH) is common among aging men. Untreated BPH may lead to complications including urinary tract infection, acute urinary retention, and obstructive nephropathy. Diagnosing BPH can be challenging because lower urinary tract symptoms are found in conditions other than BPH, and prostate size correlates poorly with symptoms of obstruction. Nonetheless, a careful medical history and physical examination, along with prudent use of diagnostic tests, can yield an accurate diagnosis. We review the evaluation of men with suspected BPH and indications for referral to a urologist for invasive therapy. We also review supporting evidence and treatment considerations for saw palmetto and the 2 major classes of prescription medications, alpha1-adrenergic antagonists and 5alpha-reductase inhibitors.

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use
  • Algorithms
  • Azasteroids / therapeutic use
  • Dutasteride
  • Enzyme Inhibitors / therapeutic use
  • Finasteride / therapeutic use
  • Humans
  • Male
  • Physical Examination
  • Prostate-Specific Antigen / blood
  • Prostatic Hyperplasia / diagnosis*
  • Prostatic Hyperplasia / drug therapy
  • Prostatic Hyperplasia / physiopathology
  • Prostatic Hyperplasia / surgery
  • Prostatic Hyperplasia / therapy*
  • Urodynamics

Substances

  • Adrenergic alpha-Antagonists
  • Azasteroids
  • Enzyme Inhibitors
  • Finasteride
  • Prostate-Specific Antigen
  • Dutasteride